EyePoint Pharmaceuticals Reports the P-II (PAVIA) Study Data of Duravyu for Non-Proliferative Diabetic Retinopathy
Shots:
- The P-II (PAVIA) study assesses Duravyu (3mg & 2mg) vs sham for the treatment of moderately-severe to severe Non-Proliferative Diabetic Retinopathy (NPDR) patients (n=77)
- The study showed stable or improved disease in 86% (3mg) & 80% (2mg) vs 70% of patients, 0% (3mg) & 5% (2mg) vs 10% of patients worsened ≥2-step and 5% (3mg) & 0% (2mg) vs 5% had ≥2-step improvement in DRSS score at 9mos.
- The company plans initiation of P-III (LUGANO) trial for Duravyu in wet AMD during H2’24 along with P-III (LUCIA) for the same indication. Additionally, P-II (VERONA) study data for DME is expected in Q1’25
Ref: EyePoint Pharmaceuticals | Image: EyePoint Pharmaceuticals
Related News:- EyePoint Pharmaceuticals Reports Results for EYP-1901 in P-II Trial for the Treatment of Wet Age-Related Macular Degeneration
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
